Patents by Inventor Kevin McDonnell
Kevin McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108738Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to natural killer (NK) cells. The invention also includes multimeric binding complexes comprising at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands or said multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by natural killer (NK) cells, such as inflammatory disorders, autoimmune disease and cancer.Type: ApplicationFiled: January 10, 2022Publication date: April 4, 2024Inventors: Nicholas KEEN, Gemma MUDD, Fay DUFORT, Katie GAYNOR, Liuhong CHEN, Phil BRANDISH, Cris LEITHEISER, Sandra UHLENBROICH, Liz REPASH, Kevin MCDONNELL
-
Publication number: 20230220008Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: November 14, 2022Publication date: July 13, 2023Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
-
Patent number: 11679080Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.Type: GrantFiled: August 23, 2022Date of Patent: June 20, 2023Assignee: TGX SOFT CHEW, LLCInventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
-
Publication number: 20230129258Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to two or more second peptide ligands, which bind to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: July 30, 2020Publication date: April 27, 2023Inventors: Punit UPADHYAYA, Johanna LAHDENRANTA, Gemma MUDD, Kevin MCDONNELL
-
Patent number: 11613560Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.Type: GrantFiled: May 11, 2020Date of Patent: March 28, 2023Assignee: BicycleTx LimitedInventors: Tom Li Stephen, Kevin McDonnell, Nicholas Keen, Liuhong Chen, Helen Harrison, Peter U. Park, Michael Skynner, Harvey Che
-
Patent number: 11608871Abstract: A shock absorbing system for force attenuation, impact modification or reduction, employs an envelope having a chamber containing a first working fluid, the envelope deformable in response to the impulse to attenuate impact force. A plurality of resilient supplemental absorber elements dispersed within the chamber. The plurality of resilient supplemental absorber elements are deformable in response to the force to assist in attenuating impact force and provide additional resilient restoring force to return the envelope to a pre-impact shape. In alternative implementations, a unitary cell for energy dissipation employs an envelope having a chamber containing a first working fluid and an inner element contained within the chamber and having an inner chamber containing a second working fluid.Type: GrantFiled: December 16, 2019Date of Patent: March 21, 2023Inventors: Kevin McDonnell, Alexandra McDonnell
-
Publication number: 20230008076Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: May 12, 2022Publication date: January 12, 2023Inventors: Nicholas KEEN, Kevin MCDONNELL, Peter PARK, Punit UPADHYAYA, Gemma Elizabeth MUDD
-
Patent number: 11542304Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: October 26, 2020Date of Patent: January 3, 2023Inventors: Liuhong Chen, Rachid Lani, Kevin Mcdonnell, Gemma Mudd, Peter U. Park, Punit Upadhyaya
-
Publication number: 20220401357Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.Type: ApplicationFiled: August 23, 2022Publication date: December 22, 2022Applicant: TGX SOFT CHEW, LLCInventors: Kevin MCDONNELL, Joanna ROSSI, Scott ECCLES, Gueorgui PUCHKAROV
-
Publication number: 20220339289Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.Type: ApplicationFiled: April 20, 2022Publication date: October 27, 2022Inventors: Kevin MCDONNELL, Gemma MUDD, Michael SKYNNER, Sophie WATCHAM
-
Patent number: 11478421Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.Type: GrantFiled: September 9, 2019Date of Patent: October 25, 2022Assignee: TGX SOFT CHEW, LLCInventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
-
Patent number: 11459032Abstract: A trailer assembly with improved lateral support structure and steering system control of the axial wheels on a front elongated trailer and a rear elongated trailer to remain in a collinear following configuration to carry elongated loads extending over the extended lengths of the combination of the front elongated trailer and the rear elongated trailer and allow ready turning control.Type: GrantFiled: December 27, 2019Date of Patent: October 4, 2022Assignee: Slingshot Haulage Pty LtdInventors: Leigh Dehne, Kevin McDonnell
-
Publication number: 20220306689Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: September 29, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Publication number: 20220306694Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: March 22, 2022Publication date: September 29, 2022Inventors: Gemma MUDD, Punit Upadhyaya, Kevin Mcdonnell
-
Patent number: 11453703Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: GrantFiled: April 2, 2019Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
-
Publication number: 20220275053Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold, characterised in that said multimeric binding complex additionally comprises a modifier group conjugated thereto. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137.Type: ApplicationFiled: August 13, 2020Publication date: September 1, 2022Inventors: Punit UPADHYAYA, Gemma Elizabeth MUDD, Kevin MCDONNELL
-
Publication number: 20220257784Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also relates to pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: July 30, 2020Publication date: August 18, 2022Applicants: BicycleTx Limited, BicycleTx LimitedInventors: Punit UPADHYAYA, Johanna LAHDENRANTA, Gemma MUDD, Kevin MCDONNELL
-
Publication number: 20220242911Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: ApplicationFiled: February 4, 2022Publication date: August 4, 2022Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA
-
Patent number: 11396530Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: October 28, 2020Date of Patent: July 26, 2022Assignee: BICYCLETX LIMITEDInventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
-
Publication number: 20220227811Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: ApplicationFiled: February 2, 2022Publication date: July 21, 2022Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA